Bimatoprost/timolol ocular insert - Allergan

Drug Profile

Bimatoprost/timolol ocular insert - Allergan

Alternative Names: Bimatoprost/timolol HELIOS™ insert - Allergan; Timolol/bimatoprost ocular insert - Allergan

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator ForSight VISION5
  • Developer Allergan
  • Class Amides; Antiglaucomas; Antihypertensives; Lipids; Morpholines; Propanolamines; Synthetic prostaglandins; Thiadiazoles
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Dec 2016 ForSight Vision5 completes a phase I/II trial in Ocular hypertension and Glaucoma in Panama (Ophthalmic) (NCT02742649)
  • 01 Mar 2016 Phase-I/II clinical trials in Glaucoma in Panama (Ophthalmic) (NCT02742649)
  • 01 Mar 2016 Phase-I/II clinical trials in Ocular hypertension in Panama (Ophthalmic) (NCT02742649)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top